Arbutus CEO exercises options for 116,408 shares

The issuer withheld 82,527 shares to satisfy the aggregate exercise prices for the President and CEO’s option exercises.

Rhea-AI Filing Summary

Arbutus Biopharma Corp (ABUS) President and CEO Lindsay Androski exercised stock options on September 18, 2026, acquiring 116,408 common shares at an exercise price of $3.20 per share and 10,456 common shares at $4.39 per share. The issuer withheld 82,527 shares, reported at $5.07 per share, to satisfy the aggregate exercise prices. No Rule 10b5-1 plan is reported.

Insider Trade Summary

126,864 shares exercised/converted

Exercise 5 txns

Insider Androski Lindsay

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	116,408	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F3	10,456	$0.00	$0.00
Exercise	Common Shares	116,408	$3.20	$373K
Exercise	Common Shares	10,456	$4.39	$46K
Exercise Price or Tax Liability	Common Shares F1	82,527	$5.07	$418K

Holdings After Transaction: Stock Option (Right to Buy) — 255,258 contracts (Direct); Common Shares — 72,337 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 82,527 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.
2. F2. The option, representing a right to purchase a total of 310,422 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 18, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.
3. F3. The option, representing a right to purchase a total of 71,700 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date.

Key Figures

Common shares acquired: 116,408 shares Exercise price: $3.20 per share Common shares acquired: 10,456 shares +5 more

8 metrics

Common shares acquired 116,408 shares Option exercise on September 18, 2026

Exercise price $3.20 per share Option exercise on September 18, 2026

Common shares acquired 10,456 shares Option exercise on September 18, 2026

Exercise price $4.39 per share Option exercise on September 18, 2026

Shares withheld 82,527 shares Withheld to satisfy aggregate exercise prices on September 18, 2026

Reported price for withheld shares $5.07 per share Shares withheld on September 18, 2026

Option share amount 310,422 shares Option grant dated March 18, 2025

Option share amount 71,700 shares Option grant dated February 2, 2026

Key Terms

Stock Option (Right to Buy), aggregate exercise prices, vests over a four-year period, continuous service

4 terms

Stock Option (Right to Buy) technical

"Stock Option (Right to Buy)"

aggregate exercise prices financial

"to satisfy the aggregate exercise prices"

vests over a four-year period technical

"vests over a four-year period"

continuous service technical

"continuous service as of each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ABUS shares did the CEO receive from exercised options?

Lindsay Androski exercised options for 116,408 common shares at $3.20 per share and 10,456 common shares at $4.39 per share on September 18, 2026. The issuer withheld 82,527 shares at a reported $5.07 per share to satisfy the aggregate exercise prices.

What were the vesting terms for Lindsay Androski’s ABUS options?

The 310,422-share option granted March 18, 2025 vests 25% on its first anniversary and the remaining 75% in substantially equal monthly installments over the next three years, subject to continuous service. The 71,700-share option granted February 2, 2026 vests in 1/48th monthly installments starting one month after its grant, also subject to continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/23/2026 - 08:32 PM Accepted by SEC EDGAR 09/23/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Androski Lindsay

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PENNSYLVANIA 18974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/18/2026		M		116,408	A	$3.2	144,408	D
Common Shares	09/18/2026		M		10,456	A	$4.39	154,864	D
Common Shares	09/18/2026		F(1)		82,527	D	$5.07	72,337	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.2	09/18/2026		M			116,408	(2)	03/18/2035	Common Shares	116,408	$0	194,014	D
Stock Option (Right to Buy)	$4.39	09/18/2026		M			10,456	(3)	02/02/2036	Common Shares	10,456	$0	61,244	D

Explanation of Responses:

1. The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 82,527 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.

2. The option, representing a right to purchase a total of 310,422 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 18, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.

3. The option, representing a right to purchase a total of 71,700 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

	/s/ Tuan Nguyen as attorney-in-fact for Lindsay Androski	09/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)